Haleon plc (NYSE:HLN) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Haleon plc (NYSE:HLN) have been given a consensus recommendation of “Moderate Buy” by the five analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company.

Several research analysts have recently issued reports on HLN shares. HSBC started coverage on shares of Haleon in a report on Wednesday, April 17th. They issued a “buy” rating on the stock. Berenberg Bank started coverage on shares of Haleon in a report on Tuesday, August 6th. They issued a “buy” rating on the stock. Finally, The Goldman Sachs Group cut shares of Haleon from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th.

Institutional Trading of Haleon

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HLN. Clearbridge Investments LLC lifted its stake in Haleon by 44.6% in the first quarter. Clearbridge Investments LLC now owns 38,446,978 shares of the company’s stock worth $326,415,000 after acquiring an additional 11,865,076 shares during the period. Wellington Management Group LLP lifted its stake in Haleon by 164.6% in the fourth quarter. Wellington Management Group LLP now owns 13,542,346 shares of the company’s stock worth $111,454,000 after acquiring an additional 8,423,475 shares during the period. Martin Investment Management LLC lifted its stake in Haleon by 12,018.4% in the first quarter. Martin Investment Management LLC now owns 4,463,205 shares of the company’s stock worth $37,893,000 after acquiring an additional 4,426,375 shares during the period. Raymond James & Associates lifted its stake in Haleon by 88.1% in the first quarter. Raymond James & Associates now owns 3,504,327 shares of the company’s stock worth $29,752,000 after acquiring an additional 1,641,715 shares during the period. Finally, Goldman Sachs Group Inc. lifted its stake in Haleon by 19.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 4,813,997 shares of the company’s stock worth $39,619,000 after acquiring an additional 772,829 shares during the period. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Stock Down 0.9 %

Shares of NYSE HLN opened at $9.72 on Tuesday. Haleon has a one year low of $7.70 and a one year high of $9.83. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.04 and a quick ratio of 0.73. The firm’s 50 day simple moving average is $8.80 and its two-hundred day simple moving average is $8.49. The stock has a market capitalization of $44.38 billion, a P/E ratio of 32.40, a PEG ratio of 2.69 and a beta of 0.24.

Haleon (NYSE:HLN) last issued its quarterly earnings results on Thursday, August 1st. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). Haleon had a net margin of 9.71% and a return on equity of 19.85%. The business had revenue of $3.50 billion for the quarter, compared to the consensus estimate of $3.55 billion. During the same quarter in the previous year, the business earned $0.08 earnings per share. As a group, analysts expect that Haleon will post 0.47 EPS for the current fiscal year.

Haleon Cuts Dividend

The company also recently announced a semi-annual dividend, which will be paid on Thursday, September 19th. Stockholders of record on Friday, August 16th will be issued a $0.0514 dividend. This represents a dividend yield of 1.6%. The ex-dividend date is Friday, August 16th. Haleon’s dividend payout ratio is 33.33%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.